Table 2.
Comparison of pertinent characteristics of our cases vis-à-vis previously reported cases.
| Age (years)/Gender | Type of diabetes | Vaccine type and dose | Time to presentation after vaccination | Diagnosis | HbA1c | Comorbidities | |
|---|---|---|---|---|---|---|---|
| Case 1 (Current report) | 20/male | T1DM | COVISHIELD (ChAdOx1 nCoV-19)- second dose | 3 days | Severe DKA | 14.1% | – |
| Case 2 (current report) | 25/female | T1DM | COVAXIN (BBV152- inactivated whole virion)- second dose | 6 days | Severe DKA | 16.3% | – |
| Zilbermint et al., n = 1 [16] | 24/female | T1DM | Moderna (mRNA-1273)- second dose | 15 h (symptom onset) | Severe DKA | 12% | Overweight |
| Mohammed A Abu-Rumaileh, n = 1 [18] | 58/male | T2DM | Pfizer-BioNTech (BNT162b2)- second dose | 6 days | HHS | 13% | Hypertension |
| Edwards et al., n = 3 [19] | |||||||
| Case 1 | 59/male | T2DM | ChAdOx1 nCoV-19- first dose | 21 days | Hyperglycemic ketosis | 14.1% | Hypertension Hypercholesterolemia |
| Case 2 | 68/male | T2DM | ChAdOx1 nCoV-19- first dose | 36 days | HHS/DKA- HHS predominant | 14.7% | Hypothyroidism |
| Case 3 | 53/male | T2DM | ChAdOx1 nCoV-19- first dose | 20 days | DKA | 17.1% | Hypertension |
| Lee et al., n = 3 [20] | |||||||
| Case 1 | 52/female | T2DM | Pfizer-BioNTech (BNT162b2)- first dose | 3 days | HHS | 12% | Hypertension, obesity |
| Case 2 | 60/male | T2DM | Moderna (mRNA-1273)- first dose | 2 days | HHS | 13.2% | Hypertension, overweight |
| Case 3 | 87/male | T2DM | Moderna (mRNA-1273)- first dose | 10 days | HHS/DKA | – | Hypertension Hyperlipidemia Ischemic stroke Congestive heart failure |